GITNUXREPORT 2025

Biomedical Industry Statistics

Biomedical industry investment, innovations, and research boost global healthcare progress.

Jannik Lindner

Jannik Linder

Co-Founder of Gitnux, specialized in content and tech since 2016.

First published: April 29, 2025

Our Commitment to Accuracy

Rigorous fact-checking • Reputable sources • Regular updatesLearn more

Key Statistics

Statistic 1

The number of biomedical startups in Europe increased by 20% from 2018 to 2023

Statistic 2

Investment in biomedical startups reached $30 billion globally in 2022

Statistic 3

85% of biomedical companies report increasing their investments in digital health initiatives

Statistic 4

The global biomedical market was valued at approximately $487 billion in 2021

Statistic 5

The biotechnology sector contributed about $83 billion to the U.S. economy in 2020

Statistic 6

The global gene therapy market is projected to reach $9.4 billion by 2027

Statistic 7

The number of diagnostic imaging procedures performed annually worldwide is estimated at over 1 billion

Statistic 8

The biopharmaceutical market accounted for nearly 55% of the total pharma market in 2022

Statistic 9

The global regenerative medicine market size was valued at over $7 billion in 2020

Statistic 10

Nearly 300 new biomedical startups are launched annually in the United States

Statistic 11

The global medical device market was valued at approximately $450 billion in 2021

Statistic 12

The top biomedical companies by revenue include Johnson & Johnson, Roche, and Pfizer

Statistic 13

The biomedical industry’s contribution to global GDP is approximately 3.5%

Statistic 14

The U.S. National Institutes of Health (NIH) grants over $41 billion annually to biomedical research

Statistic 15

The number of wearable biomedical devices sold worldwide surpassed 200 million units in 2023

Statistic 16

The global organ transplantation market is projected to reach $29 billion by 2028

Statistic 17

The average lifespan of biomedical devices on the market is approximately 7-10 years before needing significant upgrades or replacements

Statistic 18

65% of biomedical research funding is allocated towards cancer, cardiovascular, and neurological diseases

Statistic 19

The global bioinformatics market was valued at over $4 billion in 2022 and is expected to grow at a CAGR of 15%

Statistic 20

The worldwide spending on biomedical research and development is roughly $271 billion annually

Statistic 21

Approximately 40% of biomedical research funding comes from private industry

Statistic 22

The global cell therapy market is expected to reach $18 billion by 2026

Statistic 23

The global precision medicine market size is projected to reach $174 billion by 2026

Statistic 24

Medical device startups account for about 25% of all biomedical startups in the U.S.

Statistic 25

The number of FDA-approved biologic drugs increased by 20% between 2016 and 2021

Statistic 26

The number of FDA-approved gene therapies reached 5 by 2023

Statistic 27

The number of FDA-approved monoclonal antibody drugs has increased by 60% since 2015

Statistic 28

The number of FDA-approved biosimilar drugs reached 40 by 2023

Statistic 29

About 15% of current clinical trials focus on biomedical innovations

Statistic 30

70% of biomedical research funding in the U.S. comes from the federal government

Statistic 31

The average time for bringing a biomedical product from research to market is approximately 10-15 years

Statistic 32

The number of registered biomedical patents worldwide has grown by 40% since 2010

Statistic 33

The top five countries investing in biomedical research are the U.S., China, Germany, Japan, and the UK

Statistic 34

The number of personalized medicine clinical trials increased by 30% from 2018 to 2022

Statistic 35

The development cost for a new biomedical device averages around $31 million

Statistic 36

The percentage of biomedical papers published open access increased to over 50% in 2022

Statistic 37

Over 60% of biomedical innovations originate from academic institutions

Statistic 38

Biomedical sector R&D spending grew by 8% annually between 2017 and 2021

Statistic 39

The number of FDA clinical trial Investigational New Drug applications (INDs) increased by 12% during 2020-2022

Statistic 40

The number of clinical trials involving AI and machine learning in biomedical research has doubled since 2019

Statistic 41

About 10% of new drugs approved by the FDA are derived from biosynthetic biology techniques

Statistic 42

The percentage of personalized cancer vaccines reaching clinical trial stage has increased by 25% over the past 3 years

Statistic 43

The number of peer-reviewed biomedical journals published annually exceeds 4,500

Statistic 44

The percentage of biomedical research articles available open access increased from 20% in 2010 to over 55% in 2022

Statistic 45

The number of biomedical patents filed annually has increased by 35% since 2015

Statistic 46

The average number of clinical trials for biomedical products per year is around 25,000 globally

Statistic 47

The use of AI in biomedical research contributed to a 15% acceleration in drug discovery processes during 2020-2022

Statistic 48

The top five countries leading in biomedical patent filings are the U.S., China, Japan, Germany, and South Korea

Statistic 49

The number of FDA orphan drug designations in biomedical sector reached over 1,200 by 2022

Statistic 50

There are over 680,000 people employed in the biomedical sector in the United States alone

Statistic 51

The average salary for biomedical engineers in the U.S. was $92,000 in 2022

Statistic 52

50% of the biomedical workforce in the U.S. has a master’s degree or higher

Slide 1 of 52
Share:FacebookLinkedIn
Sources

Our Reports have been cited by:

Trust Badges - Publications that have cited our reports

Key Highlights

  • The global biomedical market was valued at approximately $487 billion in 2021
  • The biotechnology sector contributed about $83 billion to the U.S. economy in 2020
  • There are over 680,000 people employed in the biomedical sector in the United States alone
  • The number of FDA-approved biologic drugs increased by 20% between 2016 and 2021
  • Investment in biomedical startups reached $30 billion globally in 2022
  • About 15% of current clinical trials focus on biomedical innovations
  • The global gene therapy market is projected to reach $9.4 billion by 2027
  • The number of diagnostic imaging procedures performed annually worldwide is estimated at over 1 billion
  • 70% of biomedical research funding in the U.S. comes from the federal government
  • The average time for bringing a biomedical product from research to market is approximately 10-15 years
  • The number of registered biomedical patents worldwide has grown by 40% since 2010
  • The biopharmaceutical market accounted for nearly 55% of the total pharma market in 2022
  • The global regenerative medicine market size was valued at over $7 billion in 2020

The biomedical industry is soaring to new heights, with a valuation reaching nearly half a trillion dollars globally in 2021 and groundbreaking innovations—from gene therapies to personalized medicine—fueling its rapid growth, investment, and transformative potential.

Industry Trends

  • The number of biomedical startups in Europe increased by 20% from 2018 to 2023

Industry Trends Interpretation

The burgeoning 20% rise in European biomedical startups from 2018 to 2023 signals a continent determined to transform its health innovations from lab benches to life-saving breakthroughs.

Investment

  • Investment in biomedical startups reached $30 billion globally in 2022
  • 85% of biomedical companies report increasing their investments in digital health initiatives

Investment Interpretation

With $30 billion pouring into biomedical startups in 2022 and over 85% boosting digital health investments, the industry is clearly digitalizing itself at warp speed—transforming cutting-edge science into the healthcare of tomorrow.

Market Size and Economic Impact

  • The global biomedical market was valued at approximately $487 billion in 2021
  • The biotechnology sector contributed about $83 billion to the U.S. economy in 2020
  • The global gene therapy market is projected to reach $9.4 billion by 2027
  • The number of diagnostic imaging procedures performed annually worldwide is estimated at over 1 billion
  • The biopharmaceutical market accounted for nearly 55% of the total pharma market in 2022
  • The global regenerative medicine market size was valued at over $7 billion in 2020
  • Nearly 300 new biomedical startups are launched annually in the United States
  • The global medical device market was valued at approximately $450 billion in 2021
  • The top biomedical companies by revenue include Johnson & Johnson, Roche, and Pfizer
  • The biomedical industry’s contribution to global GDP is approximately 3.5%
  • The U.S. National Institutes of Health (NIH) grants over $41 billion annually to biomedical research
  • The number of wearable biomedical devices sold worldwide surpassed 200 million units in 2023
  • The global organ transplantation market is projected to reach $29 billion by 2028
  • The average lifespan of biomedical devices on the market is approximately 7-10 years before needing significant upgrades or replacements
  • 65% of biomedical research funding is allocated towards cancer, cardiovascular, and neurological diseases
  • The global bioinformatics market was valued at over $4 billion in 2022 and is expected to grow at a CAGR of 15%
  • The worldwide spending on biomedical research and development is roughly $271 billion annually
  • Approximately 40% of biomedical research funding comes from private industry
  • The global cell therapy market is expected to reach $18 billion by 2026
  • The global precision medicine market size is projected to reach $174 billion by 2026
  • Medical device startups account for about 25% of all biomedical startups in the U.S.

Market Size and Economic Impact Interpretation

With a valuation surpassing $487 billion, the biomedical industry is truly a trillion-dollar heartbeat of innovation—fueling groundbreaking therapies, driving economic growth (almost 3.5% of global GDP), and welcoming nearly 300 new startups annually, proving that in biotech, the future isn’t just promising—it’s precisely engineered.

Regulatory Approvals and Patents

  • The number of FDA-approved biologic drugs increased by 20% between 2016 and 2021
  • The number of FDA-approved gene therapies reached 5 by 2023
  • The number of FDA-approved monoclonal antibody drugs has increased by 60% since 2015
  • The number of FDA-approved biosimilar drugs reached 40 by 2023

Regulatory Approvals and Patents Interpretation

With biologics soaring by 20%, gene therapies limited to five, monoclonal antibodies surging 60%, and biosimilars hitting 40, the biomedical industry is clearly on a blockbuster trajectory—redefining medicine one innovative approval at a time.

Research and Development Activity

  • About 15% of current clinical trials focus on biomedical innovations
  • 70% of biomedical research funding in the U.S. comes from the federal government
  • The average time for bringing a biomedical product from research to market is approximately 10-15 years
  • The number of registered biomedical patents worldwide has grown by 40% since 2010
  • The top five countries investing in biomedical research are the U.S., China, Germany, Japan, and the UK
  • The number of personalized medicine clinical trials increased by 30% from 2018 to 2022
  • The development cost for a new biomedical device averages around $31 million
  • The percentage of biomedical papers published open access increased to over 50% in 2022
  • Over 60% of biomedical innovations originate from academic institutions
  • Biomedical sector R&D spending grew by 8% annually between 2017 and 2021
  • The number of FDA clinical trial Investigational New Drug applications (INDs) increased by 12% during 2020-2022
  • The number of clinical trials involving AI and machine learning in biomedical research has doubled since 2019
  • About 10% of new drugs approved by the FDA are derived from biosynthetic biology techniques
  • The percentage of personalized cancer vaccines reaching clinical trial stage has increased by 25% over the past 3 years
  • The number of peer-reviewed biomedical journals published annually exceeds 4,500
  • The percentage of biomedical research articles available open access increased from 20% in 2010 to over 55% in 2022
  • The number of biomedical patents filed annually has increased by 35% since 2015
  • The average number of clinical trials for biomedical products per year is around 25,000 globally
  • The use of AI in biomedical research contributed to a 15% acceleration in drug discovery processes during 2020-2022
  • The top five countries leading in biomedical patent filings are the U.S., China, Japan, Germany, and South Korea
  • The number of FDA orphan drug designations in biomedical sector reached over 1,200 by 2022

Research and Development Activity Interpretation

Despite a decade-long journey averaging 12 years from lab to market, the biomedical industry’s rapid innovation—marked by a 40% rise in patents, a doubling of AI-powered trials, and over half of research openly accessible—underscores a global race fueled by hefty investments from leading nations, with academic institutions and technological advances propelling us closer to personalized cures, even as the hefty $31 million development bill and complex regulatory landscape remind us that science still takes time.

Workforce

  • There are over 680,000 people employed in the biomedical sector in the United States alone
  • The average salary for biomedical engineers in the U.S. was $92,000 in 2022
  • 50% of the biomedical workforce in the U.S. has a master’s degree or higher

Workforce Interpretation

With over 680,000 professionals fueling innovation and earning a respectable $92,000 on average, the biomedical industry proves that cutting-edge science and advanced degrees are not just vital—they're lucrative pathways shaping America's health future.

Sources & References